CN111743996A - 一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法 - Google Patents
一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法 Download PDFInfo
- Publication number
- CN111743996A CN111743996A CN202010585669.7A CN202010585669A CN111743996A CN 111743996 A CN111743996 A CN 111743996A CN 202010585669 A CN202010585669 A CN 202010585669A CN 111743996 A CN111743996 A CN 111743996A
- Authority
- CN
- China
- Prior art keywords
- percent
- senile dementia
- improving memory
- oil
- oral emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 69
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 44
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000003921 oil Substances 0.000 claims abstract description 38
- 235000019198 oils Nutrition 0.000 claims abstract description 38
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 30
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 20
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241000195493 Cryptophyta Species 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 235000019498 Walnut oil Nutrition 0.000 claims abstract description 17
- 239000008170 walnut oil Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000020234 walnut Nutrition 0.000 claims abstract description 14
- 241000758789 Juglans Species 0.000 claims abstract description 13
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 13
- 239000000796 flavoring agent Substances 0.000 claims abstract description 12
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 11
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 10
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 10
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 10
- 239000000230 xanthan gum Substances 0.000 claims abstract description 10
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 10
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 10
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 239000011259 mixed solution Substances 0.000 claims abstract description 9
- 238000007599 discharging Methods 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 5
- 238000011049 filling Methods 0.000 claims abstract description 5
- 235000001727 glucose Nutrition 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- 230000001954 sterilising effect Effects 0.000 claims abstract description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 12
- 229960004488 linolenic acid Drugs 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 8
- 239000008347 soybean phospholipid Substances 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 4
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 4
- 235000012141 vanillin Nutrition 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 240000008790 Musa x paradisiaca Species 0.000 claims 1
- 238000004945 emulsification Methods 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 19
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 17
- 229940090949 docosahexaenoic acid Drugs 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 12
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 11
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000002526 effect on cardiovascular system Effects 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 5
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 5
- 230000003405 preventing effect Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000234295 Musa Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- 241001391944 Commicarpus scandens Species 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 101001000747 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 2A Proteins 0.000 description 1
- 101001000734 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 2B Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 1
- NCYSTSFUYSFMEO-OBLTVXDOSA-N PGI3 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C\C=C/CC)[C@H](O)C[C@@H]21 NCYSTSFUYSFMEO-OBLTVXDOSA-N 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法,涉及特殊医用食品技术领域。该具有增加记忆力改善老年痴呆口服乳剂包括藻油2‑6%;核桃油2‑6%;改性大豆磷脂5‑10%;黄原胶3‑6%;磷脂酰丝氨酸0.1‑1%;核桃肽0.5‑1%;甘油1‑5%;矫味剂0.3‑0.5%;山梨酸钾0.1‑0.2%;葡萄糖10‑20%;余量水。其制作方法为:S1,藻油、核桃油和磷酯酰丝氨酸混合均匀,制成油剂;S2,取10%的油剂,加入改性大豆磷脂和甘油,混均,加入黄原胶、矫味剂、山梨酸钾、葡萄糖和水,均质;S3,将剩下的油剂加入到混合液中,通氮气保护并均质,出料;S4,灭菌、真空消泡、灌装,得到成品。本发明制备的具有增加记忆力改善老年痴呆口服乳剂具有提高生物利用度、乳化程度高和储存期长的优点。
Description
技术领域
本发明涉及特殊医用食品技术领域,更具体地说,它涉及一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法。
背景技术
随着社会经济的发展,人们的生活水平得到了很大的提升,生活方式也发生了巨大的变化。由于吸烟、不合理膳食、超重、运动缺乏等因素使得我国心脑血管病危险趋势明显,心脑血管病的患病率处于持续上升状态。药物治疗是心脑血管最常见的治疗方式,同时在日常生活中调节饮食结构,增加促心脑血管物质的摄入,对心脑血管的治疗有更好的促进作用。食品类的物质更易被人们所接受,服用、携带便捷,没有药物较强的不良反应,可以长时间服用,同时还可以起到辅助调节心脑血管的作用。
Omega-3不饱和脂肪酸是一组多元不饱和脂肪酸,主要来源于海洋生物或深海鱼类,对人体健康尤其是心脑血管方面十分有益。Omega-3不饱和脂肪酸有助于健脑益智,保持血管畅通,预防血栓或血脂等心脑血管等疾病的发生。Omega-3不饱和脂肪酸中的二十二碳六烯酸(DHA)经口服吸收后,迅速进入细胞膜,成为膜磷脂的基本成分,膜磷脂中花生四烯酸(AA)含量减少,因而对血小板聚集有强烈作用的TXA2的生成也减少,对预防血栓的生成有很大的促进作用。Omega-3不饱和脂肪酸中的二十碳五烯酸(EPA)和DHA参与前列腺素合成代谢,对血小板有强抑制作用的前列环素I3(PGI3)的产生增加,达到预防血栓形成、抗心律失常和抗血小板聚集等作用。
由于Omega-3在体内不能自我合成,所以Omega-3不饱和脂肪酸只能从食物中摄取,而日常食品中所含少量的Omega-3不饱和脂肪酸不能满足人体的需要,故通过服用深海鱼油等以补充这类必需的不饱和脂肪酸,改善人体的健康状况。
目前,市售的富含Omega-3不饱和脂肪酸成分如二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)的保健品,主要以胶囊的形式出现,如DHA藻油软胶囊、鱼油软胶囊、磷虾油胶囊等,而胶囊中的油包载量并不多,富含Omega-3不饱和脂肪酸的油溶解性较差,不利于人体吸收,其生物利用度并不高,影响产品发挥辅助调节心脑血管的作用。
因此,需要提出一种新的方案来解决上述问题。
发明内容
针对现有技术存在的不足,本发明的目的一在于提供一种具有增加记忆力改善老年痴呆口服乳剂,其具有提高生物利用度、乳化程度高和储存期长的优点。
本发明的目的二在于提供一种具有增加记忆力改善老年痴呆口服乳剂的制作方法,其具有操作简单、适合大规模化生产的优点。
本发明的目的三在于提高一种具有增加记忆力改善老年痴呆口服乳剂在制备食品、保健品或药物中的用途。
为实现上述目的一,本发明提供了如下技术方案:
一种具有增加记忆力改善老年痴呆口服乳剂,包括如下质量百分数的组分:
藻油:2-6%;
核桃油:2-6%;
改性大豆磷脂:5-10%;
黄原胶:3-6%;
磷脂酰丝氨酸:0.1-1%;
核桃肽:0.5-1.5%;
甘油:1-5%;
矫味剂:0.3-0.5%;
山梨酸钾:0.1-0.2%;
葡萄糖:10-20%;
余量水;
所述改性大豆磷脂由大豆磷脂与不饱和脂肪酸甘油酯混合后,加入酶催化剂反应得到。
通过采用上述技术方案,藻油是海藻中全部油类物质的总称,常温下多为略带腥味的淡黄色液体,主要有效成分有EPA和DHA等,研究表明藻油具有降血脂,降血压,降胆固醇,改善血栓,预防心血管疾病的作用,给高血脂人食用1.5gDHA,2-15周之后,甘三酯含量降低了14-26%,高密度脂蛋白含量有明显的上升趋势。
核桃油为高级保健食用油,不饱和脂肪酸含量≥92%,亚油酸Ω-6≥56%,亚麻酸Ω-3≥14%,富含天然VA、VD等营养物质。核桃油有健脑养脑的作用,核桃油中不含胆固醇,可有效预防老年痴呆症的发生,丰富的亚油酸和亚麻酸能排除血管内新陈代谢的杂质,使血液净化,为大脑提供新鲜血液。
核桃肽是将核桃去除油脂后,以核桃粕为原料,利用生物酶解技术,从核桃蛋白中提取而成的小分子物质,它富含人体必需的18中氨基酸,是一种新型营养物质,不仅具有健脑功能,同时有着核桃并不具备的营养功效。核桃肽的主要功效有:提高记忆力、安眠、改善消化系统,促进营养物质吸收、辅助治疗心脑血管疾病、提高人体免疫力和抗癌,抑制癌细胞增长。
改性大豆磷脂与未经改性天然大豆磷脂相比,其具有更好的乳化性和生理活性,可替代常用的吐温-80乳化剂,安全、可靠。从乳化性能看,大豆磷脂通过改性后,其HPL值=10左右,此时获得改性大豆磷脂与油剂和水剂互溶性较好,且获得的乳剂不易破乳,后期保质期可以达到2年左右;从生理活性看,改性大豆磷脂是通过酯交换反应将中碳链油脂、共轭亚油酸、植物淄醇或n-3系列多不饱和脂肪酸等不饱和脂肪酸引入磷脂分子中而获得,改性大豆磷脂不仅保持了磷脂良好的乳化特性,而且还使磷脂的营养价值得到大幅的改善,与藻油、核桃油和磷脂酰丝氨酸配合使用具有较好的促进吸收效果。改性大豆磷脂类似于血脑屏障的钥匙或载体,运载着藻油中DHA和核桃油中亚麻酸Ω-3等营养成分通过血脑屏障进入到脑部,给人体脑部补充营养,提高记忆力,预防老年痴呆。
进一步优选为,所述具有增加记忆力改善老年痴呆口服乳剂包括如下质量百分数的组分:
藻油:3.5%;
核桃油:3.5%;
改性大豆磷脂:7%;
黄原胶:4.5%;
磷脂酰丝氨酸:0.5%;
核桃肽:1%;
甘油:2.5%;
矫味剂:0.4%;
山梨酸钾:0.165%;
葡萄糖:15%;
水:62.935%。
通过采用上述技术方案,各营养物质之间达到最优比,营养成分的吸收率、利用率最高,吸收效果较好。
进一步优选为,所述具有增加记忆力改善老年痴呆口服乳剂每1g含有效组分为:DHA:14mg;
磷脂酰胆碱:25mg;
磷脂酰丝氨酸:5mg;
α-亚麻酸:3.5mg。
通过采用上述技术方案,DHA为藻油中的有效成分,学名为二十二碳六烯酸,是大脑皮质、中枢神经系统和视网膜的重要构成成分,DHA在体内水平的高低会直接影响脑细胞的增值、神经传导、突触的生长和发育。磷脂酰胆碱,即卵磷脂,为人体营养需要物质,对血清脂质具有调节作用,具有提高脑细胞的活性化程度,提高记忆与智力水平。磷脂酰丝氨酸又称复合神经酸,是细胞膜的活性物质,尤其存在于大脑细胞中,其功能主要是改善神经细胞功能,调节神经脉冲的传导,增进大脑记忆功能,由于其具有很强的亲脂性,吸收后能迅速通过血脑屏障进入大脑,起到舒缓血管平滑肌细胞,增加脑部供血的作用。α-亚麻酸是有三个双键的多元不饱和脂肪酸,是一种ω-3必需脂肪酸,用于提高智力作用,抗血栓、保肝等,是人们必须的营养素之一。上述各营养成分合理搭配,具有较好的改善记忆力,预防老年痴呆的作用,且各组分含量复合国际要求。
进一步优选为,所述矫味剂由香兰素和香蕉香精按照质量比为2:3组成的混合物。
通过采用上述技术方案,食用者食用口服乳剂时,其中的香兰素和香蕉香精扩散到口中,从而完全遮盖住乳剂中原料组分的不良气味,使得乳剂更易食用。
进一步优选为,所述具有增加记忆力改善老年痴呆口服乳剂中还含有0.1-1%的抗氧化剂,所述抗氧化剂采用维生素C和/或维生素E。
通过采用上述技术方案,维生素C和维生素E两者本身就有提高人体免疫力和保护肝脏的租用,加入到乳剂中,具有抗氧化、抗自由基协同作用,可延长口服乳剂的保质期限。
进一步优选为,所述具有增加记忆力改善老年痴呆口服乳剂的粒径为300-550nm。
通过采用上述技术方案,乳剂是一种液体制剂,为多相相互分散形成的非均相液体分散体系,通过将本发明中的乳剂的粒径控制在300-550nm之间,得到的乳剂更加稳定,保质期较长。
为实现上述目的二,本发明提供了如下技术方案:
一种具有增加记忆力改善老年痴呆口服乳剂的制作方法,包括以下步骤:
S1,藻油、核桃油、磷酯酰丝氨酸和核桃肽混合均匀,制成油剂;
S2,取10%的油剂,加入改性大豆磷脂和甘油,混合均匀,然后加入黄原胶、矫味剂、山梨酸钾、葡萄糖和水,采用均质机在常温下进行均质混合10-20min,得到混合液;
S3,将剩下的油剂加入到混合液中,通入氮气保护,于40-60℃下,采用均质机均质0.5-1h,出料;
S4,灭菌、真空消泡、灌装,得到具有增加记忆力改善老年痴呆口服乳剂的成品。
通过采用上述技术方案,本发明采用分布混合乳化的方式,将各原料按顺序并逐步加入到混合体系中,使其充分分散乳化,得到的口服乳剂分散稳定,稳定性高,储存期较长。
综上所述,与现有技术相比,本发明具有以下有益效果:
(1)本发明采用改性大豆磷脂替代常用的乳化剂吐温-80,其具有更好的乳化性和生理活性,与油剂和水剂互溶性较好,且获得的乳剂不易破乳,后期保质期可以达到2年左右;
(2)本发明采用改性大豆磷脂作为乳化剂,其不仅保持了磷脂良好的乳化特性,而且还使磷脂的营养价值得到大幅的改善,与藻油、核桃油和磷脂酰丝氨酸配合使用具有较好的促进吸收效果。改性大豆磷脂类似于血脑屏障的钥匙或载体,运载着藻油中DHA和核桃油中亚麻酸Ω-3等营养成分通过血脑屏障进入到脑部,给人体脑部补充营养,提高记忆力,预防老年痴呆;
(3)本发明中的各有效成分均严格控制加入量和含量,其合理搭配,具有较好的改善记忆力,预防老年痴呆的作用,且各组分含量复合国际要求。
附图说明
图1为本申请中具有增加记忆力改善老年痴呆口服乳剂的制备工艺流程图。
具体实施方式
下面结合附图和实施例,对本发明进行详细描述。
本发明中,具有增加记忆力改善老年痴呆口服乳剂每1g含有效组分为:DHA:14mg;磷脂酰胆碱:25mg;磷脂酰丝氨酸:5mg;α-亚麻酸:3.5mg,符合国家要求。
矫味剂为香兰素和香蕉香精按照质量比为2:3组成的混合物。
实施例1:一种具有增加记忆力改善老年痴呆口服乳剂,各组分及其相应的质量百分数如表1所示,如图1所示,并通过如下步骤制备获得:
S1,藻油、核桃油、磷酯酰丝氨酸和核桃肽混合均匀,制成油剂;
S2,取10%的油剂,加入改性大豆磷脂和甘油,混合均匀,然后加入黄原胶、矫味剂、山梨酸钾、葡萄糖和水,采用均质机在常温下,800r/min转速下均质混合20min,得到混合液;
S3,将剩下的油剂加入到混合液中,通入氮气保护,于40℃下,1200r/min转速下,均质1h,出料;
S4,升温至110℃,保温45min进行灭菌,然后开启水环真空泵,调节真空-0.9Mpa,进行消泡,最后出料灌装,得到平均粒径为300nm的具有增加记忆力改善老年痴呆口服乳剂的成品。
本实施例中的改性大豆磷脂的制作方法为:
将质量比为1:10的大豆磷脂与1,3-亚麻油甘油二酯充分搅拌混合,加热至60℃,转速300r/min下搅拌90min,然后加入大豆磷脂质量2%的磷脂酶D,控制反应温度60℃,pH=8,反应时间36h,反应结束后快速升温至100℃进行酶灭活,并于2000r/min下低速离心10min,除去下层失活酶,加入10%无水丙酮,于300r/min下搅拌30min,除去上层丙酮层,-20℃下冷冻干燥,即得改性大豆磷脂。
实施例2-6:一种具有增加记忆力改善老年痴呆口服乳剂,与实施例1的不同之处在于,各组分及其相应的质量百分数如表1所示。
表1实施例1-6中各组分及其质量百分数
实施例7:一种具有增加记忆力改善老年痴呆口服乳剂,与实施例1的不同之处在于,通过如下步骤制备获得:
S1,藻油、核桃油、磷酯酰丝氨酸和核桃肽混合均匀,制成油剂;
S2,取10%的油剂,加入改性大豆磷脂和甘油,混合均匀,然后加入黄原胶、矫味剂、山梨酸钾、葡萄糖和水,采用均质机在常温下,1000r/min转速下均质混合10min,得到混合液;
S3,将剩下的油剂加入到混合液中,通入氮气保护,于60℃下,1400r/min转速下,均质0.5h,出料;
S4,升温至110℃,保温45min进行灭菌,然后开启水环真空泵,调节真空-0.9Mpa,进行消泡,最后出料灌装,得到平均粒径为500nm的具有增加记忆力改善老年痴呆口服乳剂的成品。
实施例8:一种具有增加记忆力改善老年痴呆口服乳剂,与实施例1的不同之处在于,步骤S2中还加入有0.1%质量百分数的抗氧化剂,本实施例中的抗氧化剂采用维生素C。
实施例9:一种具有增加记忆力改善老年痴呆口服乳剂,与实施例1的不同之处在于,步骤S2中还加入有1%质量百分数的抗氧化剂,本实施例中的抗氧化剂采用维生素E。
实施例10:一种具有增加记忆力改善老年痴呆口服乳剂,与实施例1的不同之处在于,步骤S2中还加入有0.5%质量百分数的抗氧化剂,本实施例中的抗氧化剂为维生素C和维生素E按照质量比1:1组成的混合物。
对比例1:一种口服乳剂,与实施例1的不同之处在于,采用吐温-80替代实施例1中的改性大豆磷脂。
对比例2:一种口服乳剂,与实施例1的不同之处在于,采用大豆磷脂替代实施例1中的改性大豆磷脂。
对比例3:一种口服乳剂,所述口服乳剂每1g含有效组分为:磷脂酰胆碱:25mg;磷脂酰丝氨酸:5mg;α-亚麻酸:3.5mg。与实施例1的不同之处在于,本对比例中,DHA的含量为0。
对比例4:一种口服乳剂,所述口服乳剂每1g含有效组分为:DHA:14mg;磷脂酰丝氨酸:5mg;α-亚麻酸:3.5mg。与实施例1的不同之处在于,本对比例中,磷脂酰胆碱的含量为0。
对比例5:一种口服乳剂,所述口服乳剂每1g含有效组分为:DHA:14mg;磷脂酰胆碱:25mg;α-亚麻酸:3.5mg。与实施例1的不同之处在于,本对比例中,磷脂酰丝氨酸的含量为0。
对比例6:一种口服乳剂,所述口服乳剂每1g含有效组分为:DHA:14mg;磷脂酰胆碱:25mg;磷脂酰丝氨酸:5mg。与实施例1的不同之处在于,本对比例中,α-亚麻酸的含量为0
对比例6:
性能测试
生物利用度测试:选取雄性Wistar大鼠,体重260-280g共160只,平均分为16组,实验前禁食12h,不禁水。给大鼠分别灌胃实施例1-10和对比例1-5中的乳剂,在给药0.25h,0.5h,1h,2h,4h,6h,8h,12h和24h后,眼眶静脉丛采血0.5mL,收集于肝素化试管中,37℃水浴保温30min后,5000r/min下低温离心10min,分离血浆取上清液,于-20℃保存待测定其药物浓度。其血液浓度-时间曲线测定数据经过DAS药动学计算后计入下表2中。
由表2中测试数据可以看出,实施例1-10中大鼠对乳剂的生物利用度明显要高于对比例1-6中大鼠对乳剂的生物利用度,尤其实施例9-10为最优实施例,其生物利用度最高。
表2DHA生物利用度测试结果
T<sub>max</sub>(h) | C<sub>max</sub>(μg/mL) | AUC<sub>0-24h</sub>(mg·h/mL) | |
实施例1 | 8.36 | 435.65 | 7.68 |
实施例2 | 8.35 | 438.15 | 7.86 |
实施例3 | 8.36 | 439.84 | 7.98 |
实施例4 | 8.40 | 438.28 | 7.84 |
实施例5 | 8.41 | 431.25 | 7.89 |
实施例6 | 8.47 | 428.95 | 7.84 |
实施例7 | 8.42 | 427.76 | 7.79 |
实施例8 | 8.46 | 431.86 | 7.80 |
实施例9 | 8.32 | 445.65 | 7.98 |
实施例10 | 8.34 | 446.32 | 8.01 |
对比例1 | 9.82 | 195.99 | 2.86 |
对比例2 | 9.65 | 215.36 | 3.52 |
对比例3 | 9.95 | 189.38 | 3.21 |
对比例4 | 9.36 | 214.52 | 3.85 |
对比例5 | 9.15 | 214.26 | 3.41 |
对比例6 | 9.18 | 218.53 | 3.64 |
以上所述仅是本发明的优选实施方式,本发明的保护范围并不仅局限于上述实施例,凡属于本发明思路下的技术方案均属于本发明的保护范围。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理前提下的若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (8)
1.一种具有增加记忆力改善老年痴呆口服乳剂,其特征在于,包括如下质量百分数的组分:
藻油:2-6%;
核桃油:2-6%;
改性大豆磷脂:5-10%;
黄原胶:3-6%;
磷脂酰丝氨酸:0.1-1%;
核桃肽:0.5-1.5%;
甘油:1-5%;
矫味剂:0.3-0.5%;
山梨酸钾:0.1-0.2%;
葡萄糖:10-20%;
余量水;
所述改性大豆磷脂由大豆磷脂与不饱和脂肪酸甘油酯混合后,加入酶催化剂反应得到。
2.根据权利要求1所述的具有增加记忆力改善老年痴呆口服乳剂,其特征在于,所述具有增加记忆力改善老年痴呆口服乳剂包括如下质量百分数的组分:
藻油:3.5%;
核桃油:3.5%;
改性大豆磷脂:7%;
黄原胶:4.5%;
磷脂酰丝氨酸:0.5%;
核桃肽:1%;
甘油:2.5%;
矫味剂:0.4%;
山梨酸钾:0.165%;
葡萄糖:15%;
水:62.935%。
3.根据权利要求1所述的具有增加记忆力改善老年痴呆口服乳剂,其特征在于,所述具有增加记忆力改善老年痴呆口服乳剂每1g含有效组分为:
DHA:14mg;
磷脂酰胆碱:25mg;
磷脂酰丝氨酸:5mg;
α-亚麻酸:3.5mg。
4.根据权利要求1所述的具有增加记忆力改善老年痴呆口服乳剂,其特征在于,所述矫味剂由香兰素和香蕉香精按照质量比为2:3组成的混合物。
5.根据权利要求1所述的具有增加记忆力改善老年痴呆口服乳剂,其特征在于,所述具有增加记忆力改善老年痴呆口服乳剂中还含有0.1-1%的抗氧化剂,所述抗氧化剂采用维生素C和/或维生素E。
6.根据权利要求1-5任一项所述的具有增加记忆力改善老年痴呆口服乳剂,其特征在于,所述具有增加记忆力改善老年痴呆口服乳剂的粒径为300-550nm。
7.根据权利要求6所述的具有增加记忆力改善老年痴呆口服乳剂的制作方法,其特征在于,包括以下步骤:
S1,藻油、核桃油、磷酯酰丝氨酸和核桃肽混合均匀,制成油剂;
S2,取10%的油剂,加入改性大豆磷脂和甘油,混合均匀,然后加入黄原胶、矫味剂、山梨酸钾、葡萄糖和水,采用均质机在常温下进行均质混合10-20min,得到混合液;
S3,将剩下的油剂加入到混合液中,通入氮气保护,于40-60℃下,采用均质机均质0.5-1h,出料;
S4,灭菌、真空消泡、灌装,得到具有增加记忆力改善老年痴呆口服乳剂的成品。
8.根据权利要求6所述的具有增加记忆力改善老年痴呆口服乳剂在制备食品、保健品或药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010585669.7A CN111743996A (zh) | 2020-06-24 | 2020-06-24 | 一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010585669.7A CN111743996A (zh) | 2020-06-24 | 2020-06-24 | 一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111743996A true CN111743996A (zh) | 2020-10-09 |
Family
ID=72676952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010585669.7A Pending CN111743996A (zh) | 2020-06-24 | 2020-06-24 | 一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111743996A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114680336A (zh) * | 2020-12-30 | 2022-07-01 | 云南汉盟制药有限公司 | 一种含火麻仁不饱和脂肪酸的滴剂及其制备方法 |
CN117397810A (zh) * | 2023-11-07 | 2024-01-16 | 广东金海康医学营养品股份有限公司 | 一种dha藻油特膳饮及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005319A1 (en) * | 1992-09-02 | 1994-03-17 | Taiyo Gyogyo Kabusiki Kaisya | Brain function ameliorant composition, learning capacity enhancer, mnemonic agent, dementia preventive, dementia curative, or functional food with brain function ameliorant effect |
US20060241080A1 (en) * | 2003-10-22 | 2006-10-26 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
CN102827886A (zh) * | 2012-08-06 | 2012-12-19 | 广州城市职业学院 | 一种分子控制技术制备质构大豆卵磷脂的方法 |
CN107296100A (zh) * | 2017-07-12 | 2017-10-27 | 温州市香格里拉食品有限公司 | 一种含有dha藻油与核桃肽的复合粉及其制备方法 |
CN110123753A (zh) * | 2019-06-18 | 2019-08-16 | 宁波仙健海嘉生物科技有限公司 | 一种口服微乳及其制备方法和应用 |
-
2020
- 2020-06-24 CN CN202010585669.7A patent/CN111743996A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005319A1 (en) * | 1992-09-02 | 1994-03-17 | Taiyo Gyogyo Kabusiki Kaisya | Brain function ameliorant composition, learning capacity enhancer, mnemonic agent, dementia preventive, dementia curative, or functional food with brain function ameliorant effect |
US20060241080A1 (en) * | 2003-10-22 | 2006-10-26 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
CN102827886A (zh) * | 2012-08-06 | 2012-12-19 | 广州城市职业学院 | 一种分子控制技术制备质构大豆卵磷脂的方法 |
CN107296100A (zh) * | 2017-07-12 | 2017-10-27 | 温州市香格里拉食品有限公司 | 一种含有dha藻油与核桃肽的复合粉及其制备方法 |
CN110123753A (zh) * | 2019-06-18 | 2019-08-16 | 宁波仙健海嘉生物科技有限公司 | 一种口服微乳及其制备方法和应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114680336A (zh) * | 2020-12-30 | 2022-07-01 | 云南汉盟制药有限公司 | 一种含火麻仁不饱和脂肪酸的滴剂及其制备方法 |
CN117397810A (zh) * | 2023-11-07 | 2024-01-16 | 广东金海康医学营养品股份有限公司 | 一种dha藻油特膳饮及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU666246B2 (en) | Nutritional product for persons having a neurological injury | |
RU2093996C1 (ru) | Способ добавления в детскую питательную смесь докозагексановой кислоты и арахидоновой кислоты (варианты) и композиция (варианты) | |
JP5860704B2 (ja) | 水中オメガ−3強化された魚油型非経口栄養エマルション | |
RU2120998C1 (ru) | Способ получения масла, содержащего арахидоновую кислоту, немодифицированное микробное масло, способ обеспечения арахидоновой кислотой смеси для детского питания, косметическая композиция, питание или питательная добавка, способ лечения людей и смесь для детского питания | |
US5574065A (en) | Method and composition for normalizing injury response | |
EP0660708A1 (en) | Phospholipids | |
SG191784A1 (en) | Nutritional products including a novel fat system including monoglycerides | |
CN1891214A (zh) | 对白天活动量减少及/或抑郁症状具有改善作用的组合物 | |
CN111743996A (zh) | 一种具有增加记忆力改善老年痴呆口服乳剂及其制作方法 | |
TWI503117B (zh) | A pharmaceutical composition and a food and medicine for preventing or ameliorating a symptom or a disease caused by aging of the blood vessel caused by a decrease in blood vessel elasticity, a method for producing the same, and arachidonic acid and / or arachidonic acid The use of fatty acid compounds for the manufacture of drugs (2) | |
CN101167793A (zh) | 核桃油脂肪乳剂及其制造方法 | |
CN113575698B (zh) | 一种鱼油软胶囊及其制备方法和应用 | |
AU634537B2 (en) | Pharmaceutical lipid composition for parenteral nutrition | |
JPH08169824A (ja) | 小児科脂質乳剤 | |
EP0055172B1 (fr) | Composition à usage thérapeutique à base d'hydrolysats de protéines et de lipides riches en acides gras polyinsaturés | |
CN103445186A (zh) | 一种婴幼儿专用海洋蛋白粉及制备方法 | |
CN104189058B (zh) | 一种含左卡尼汀的脂肪乳注射液 | |
CN107232324B (zh) | 一种含有大豆磷脂的健康平衡油及其制备方法和用途 | |
CN114680336A (zh) | 一种含火麻仁不饱和脂肪酸的滴剂及其制备方法 | |
CN113303467A (zh) | 一种适用于1~10岁脂代谢异常患儿的肠内营养粉剂及其制备方法 | |
JPH11343236A (ja) | 多価不飽和脂肪酸を含有する医薬組成物および健康食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |